You are here

Technology in Cancer Research & Treatment

Technology in Cancer Research & Treatment

2016 Impact Factor: 2.204
2016 Ranking: 150/217 in Oncology
Source: 2016 Journal Citation Reports® (Clarivate Analytics, 2017); Indexed in PubMed: MEDLINE

Managing Editor
Jennifer Lovick, PhD University of California, Los Angeles SAGE Publishing, Thousand Oaks, CA USA

eISSN: 15330338 | ISSN: 15330346 | Current volume: 16 | Current issue: 5 Frequency: Bi-monthly
Now Open Access!

- Impact Factor of 2.204
- Focus on prevention, diagnosis, treatment, and monitoring of cancer
- Fast and double-blind peer review by dedicated Associate Editors and Editorial Board Members
- Global visibility due to international audience of multidisciplinary researchers
- Article Processing Charge (APC) of $1000 USD is payable upon acceptance

Technology in Cancer Research and Treatment (TCRT) is a broad-spectrum, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and discuss developments in the prevention, diagnosis, treatment, and monitoring of cancer.

Visit the Aims and Scope page for details on article types and topics of particular interest.

This journal is a member of the Committee on Publication Ethics (COPE).

Manuscript Submission

Why Publish Open Access with TCRT

  • Visibility and Impact: Anyone anywhere in the world can read, use and cite your research
  • Rigorous Standards: Double-blind peer review policy
  • Speed: Less than 2 months from submission to first decision and 4 weeks from acceptance to online publication
  • Flexibility: No page limits or page charges, and authors can publish full data sets, figures, tables, etc
  • Copyright: Authors retain copyright under a Creative Commons License

Useful Links

Technology in Cancer Research and Treatment (TCRT) is a JCR-ranked, broad-spectrum, open access, peer-reviewed publication whose aim is to provide researchers and clinicians with a platform to share and discuss developments in the prevention, diagnosis, treatment, and monitoring of cancer.

Article Types and Topics of Interest
TCRT welcomes original research (both basic and clinical studies), reviews, and commentaries. We encourage submissions relating to advances in the following areas:

Preventative or Diagnostic
  • Biomarkers (genes, genetic abnormalities, RNA, proteins, hormones, enzymes)
  • Methods of biomarker detection
  • Cancer biology (cell and molecular biology, immune response, tumor biology, tumor microenvironment)
  • Genetic (DNA damage and repair, epigenetics, gene regulation)
  • Proteomics, Genomics, Systems Biology
  • Epidemiology
  • Imaging technologies (CT scan, MRI, X-ray, Ultrasound)
  • Nuclear medicine scan (Bone, PET, Thyroid, MUGA, Gallium)
  • Biopsy (endoscopic, needle)
  • Emerging technologies
  • Novel applications of existing technologies


Treatment or Monitoring

  • Stem cell transplantation
  • Precision/Personalized medicine, Targeted therapy (antibodies, small-molecule drugs)
  • Immunotherapy (adoptive cell transfer, BCG, cytokines, gene therapy, gene transfer, monoclonal antibodies, oncolytic virotherapy, vaccines)
  • Surgery (open or minimally-invasive)
  • Chemotherapy
  • Hormone therapy
  • Radiation therapy (external beam or internal), Brachytherapy
  • Cryosurgery/Cryotherapy
  • Laser therapy (laser-induced interstitial thermotherapy (LITT), interstitial laser photocoagulation)
  • Hyperthermia therapy/Thermal therapy/Thermotherapy
  • Photodynamic therapy (PDT)
  • Irreversible electroporation (IRE)
  • Emerging technologies or novel applications of existing ones

Click here to see a selection of the latest papers published in TCRT

Manuscript Submission

Executive Editor
Jennifer K. Lovick, PhD SAGE Publishing, Thousand Oaks, CA USA
Founding Editor
Mukti H. Sarma, PhD University at Albany - SUNY, New York, USA
Associate Editor - Chemo/Combinatorial Therapies
Timo L.M. Ten Hagen, PhD Erasmus MC, Netherlands
Associate Editor - Cryotherapy/Biothermal Technology
Yoed Rabin, DSc Carnegie Mellon University, Pittsburgh, USA
Associate Editor - Immunotherapy
Satiro De Oliveira David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Associate Editor - Medical Physics and Imaging
Xin Zhang, PhD University of Arkansas for Medical Sciences, Little Rock, AR, USA
Kujtim Latifi, PhD Moffitt Cancer Center, Tampa, FL USA
Associate Editor - Methylation
Mukesh Verma, PhD National Institutes of Health, Bethesda, Maryland, USA
Associate Editor - Radiation and Cancer Biology
Robert Griffin, PhD University of Arkansas, Little Rock
Associate Editor - Thermal Therapies
Truls E. Bjerklund Johansen Oslo University Hospital, Norway
Associate Editor - Tumor Biology
Amir Goldkorn USC Norris Comprehensive Cancer Center & Keck School of Medicine, CA, USA
Paola Maycotte Centro de Investigación Biomédica de Oriente, Puebla, Mexico
Consulting Editor
Umair Shafique, MSc SAGE Publishing, Thousand Oaks, CA USA
Editorial Board
Abass Alavi, MD University of Pennsylvania, Philadelphia, USA
Robert Alfano, PhD The City College Of New York, CUNY
Filippo Alongi, MD Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy
Mario Ammirati, MD, MBA St. Rita Medical Center/Mercy Health, Lima OH, USA
John G. Baust, PhD State University of New York, Binghamton, USA
Stewart Becker, PhD New York University, Langone Medical Center, USA
Dzevad Belkic, PhD Karolinska Institute, Stockholm, Sweden
Karen Belkic, MD, PhD Claremont Graduate University, California, USA
Max K. Bulsara The University of Notre Dame, Australia
George A. Calin, MD, PhD The University of Texas M.D. Anderson Cancer Center, Houston, USA
Maja Cemazar, PhD Institute of Oncology, Ljubljana, Slovenia
Jeffrey J. Chalmers, PhD Ohio State University, Columbus, USA
Gregory Czarnota, MD, PhD Sunnybrook Research Institute, University of Toronto, Canada
Hadassa Degani, PhD The Weizmann Institute of Science, Israel
Ayman El-Baz, PhD University of Louisville, Kentucky, USA
Adel K. El-Naggar, MD, PhD The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Antonella Fogliata, PhD Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Andrew A. Gage, MD State University of New York, Buffalo, USA
Roberto Gambari, PhD University of Ferrara, Italy
Sanjiv Sam Gambhir Michigan State University, East Lansing, MI, USA
A.H. Gandjbakhche, PhD National Institutes of Health, Bethesda, Maryland, USA
Uwe Haberkorn, PhD University of Heidelberg, Germany
Garret M. Hampton, PhD Genomics Institute of the Novartis Research Foundation, California, USA
Samir Hanash, MD, PhD Fred Hutchinson Cancer Research Center, Washington, USA
Richard Heller, PhD Old Dominion University, Virginia
Dwight Heron, MD University of Pittsburgh Cancer Institute, Pennsylvania, USA
David Isaacson, PhD Rensselaer Polytechnic Institute, New York
Samie R. Jaffrey, MD, PhD Cornell University, New York, USA
Kewal K. Jain, MD Pharmabiotech, Switzerland
Tomas Kron, PhD Peter MacCallum Cancer Center, Australia
David Larson, MD, PhD University of California, San Francisco, USA
Frederick Locke, MD Moffitt Cancer Center, Florida
Jay Loeffler, MD, FACR, FASTRO Massachusetts General Hospital, Boston, USA
Kenneth Lundstrom, PhD PanTherapeutics, Switzerland
Lijun Ma, PhD University of California, San Francisco, USA
Paulette McCormick, PhD University at Albany - SUNY, New York, USA
William M. Mendenhall, MD Shands Cancer Center, Florida, USA
Arlan H. Mintz, MD University of Pittsburgh, Pennsylvania, USA
Filippo Molinari, PhD Politecnico di Torino, Italy
Sten Myrehaug, PhD Sunnybrook Health Sciences Centre, University of Toronto, Canada
Subir Nag, MD Kaiser Permanente, Santa Clara, California, USA
Orhan Nalcioglu, PhD, FIEEE, FAAPM University of California, Irvine, USA
Yin Kwee Ng, PhD Nanyang Technological University, Singapore
Dattatreyudu Nori, MD, FACR New York Presbyterian Hospital, USA
Dilini Pinnaduwage, PhD University of California, San Francisco, USA
Tomasz Piotrowski Greater Poland Cancer Center, Poznan, Poland
Veena N. Rao, PhD Morehouse School of Medicine, Atlanta, GA, USA
William F. Regine, MD University of Maryland, Baltimore, USA
Thomas Reid, MD National Cancer Institute, Bethesda, Maryland, USA
David Roberge, MD McGill University, Canada
Arjun Sahgal, MD University of Toronto, Canada
Berkman Sahiner, PhD University of Michigan, Ann Arbor, USA
Michael L. Salgaller, PhD National Cancer Institute, MD, USA
Daniel Scherman, PhD INSERM, France
Reinhard Schulte, MD Loma Linda University, California, USA
Eva M. Sevick-Muraca, PhD University of Texas Health Sciences Center, Houston, USA
Richard Simpson, PhD University of Arizona, Tucson, AZ, USA
Keshav Singh, PhD University of Alabama, Birmingham, USA
Luis Souhami, MD McGill University, Canada
Gunnar Steineck University of Gothenburg, Gothenburg, Sweden
H. Cuneyt Ulutin, MD, PhD Yeni Yuzyil University, Turkey
Xiaoying Wang, PhD Tianjin University of Traditional Chinese Medicine, Tianjin, China
James S. Welsh, MS, MD, FARCO Stritch School of Medicine Loyola University- Chicago, USA
Andrew Wroe, PhD, DABR Loma Linda University Medical Center, USA
Sue S. Yom, MD, PhD University of California, San Francisco, USA
Cedric Yu, PhD University of Maryland, Baltimore, USA
Wenwei Yu, PhD Chiba University, Japan
Baohong Yuan, PhD University of Texas, Arlington, USA
Ning J. Yue, PhD, FAAPM Rutgers Robert Wood Johnson Medical School, New Jersey, USA
Marco Zaider, PhD Memorial Sloan Kettering Cancer Center, New York, USA
Nikolai Zhelev, PhD, CBiol, EurProBiol Abertay University, Scotland
Wei Zheng, PhD The University of Texas M.D. Anderson Cancer Center, Houston, USA
Abdullah Faruk Zorlu, MD Hacettepe University, Turkey
  • EMBASE/Excerpta Medica
  • Index Medicus
  • Science Citation Index Expanded (Web of Science)
  • Scopus
  • This Journal is a member of the Committee on Publication Ethics

    This Journal recommends that authors follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals formulated by the International Committee of Medical Journal Editors (ICMJE)

    Please read the complete author guidelines then visit the Journal’s submission site to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

    Only manuscripts of sufficient quality that meet the aims and scope of Technology in Cancer Research and Treatment will be reviewed.

    As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

    Open Access
    In 2017, Technology in Cancer Research and Treatment will transition to Open Access publication; all articles will be freely available online immediately upon publication.

    All articles are rigorously peer-reviewed, and brought to publication as rapidly as possible. Production costs are covered by Article Processing Charges (APC) paid by the author/institution/funder upon acceptance of their manuscript (more information below). There is no charge for submitting a paper to Technology in Cancer Research and Treatment.This journal publishes manuscripts under Creative Commons licenses. The standard license is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.

    For general information on Open Access at SAGE and Open Access FAQs, visit this page.

    Article Processing Charge (APC)
    Upon acceptance of your manuscript, you will be charged an introductory one-time Article Processing Charge (APC) of $1,000 USD, discounted from the full rate of $2,000 USD. This fee covers the cost of publication and ensures that your article will be freely available. This introductory rate is available for a limited time. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 20 working days.

    Peer review policy
    The journal’s policy is that manuscripts are reviewed by two expert reviewers. All manuscripts are reviewed as rapidly as possible, while maintaining rigor. Reviewers make comments to the author and recommendations to the Associate Editors who then make their final decision.

    Further information
    Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Technology in Cancer Research and Treatment editorial office as follows:

    Jennifer Lovick, PhD, Executive Editor